943320-60-3

Basic information

• Product Name: IMidazo[1,2-b]pyridazine, 3-[2-(triMethylsilyl)ethynyl]-
• Synonyms: IMidazo[1,2-b]pyridazine, 3-[2-(triMethylsilyl)ethynyl]-;3-(2-(triMethylsilyl)ethynyl)iMidazo[1,2-b]pyridazine;3-((trimethylsilyl)ethynyl)imidazo[1,2-b]pyridazine;2-imidazo[1,2-b]pyridazin-3-ylethynyl(trimethyl)silane
• CAS NO: 943320-60-3
• Molecular Formula: C₁₁H₁₃N₃Si
• Molecular Weight: 215.32652
• Mol File: 943320-60-3.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• CAS DataBase Reference: IMidazo[1,2-b]pyridazine, 3-[2-(triMethylsilyl)ethynyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-b]pyridazine, 3-[2-(triMethylsilyl)ethynyl]-(943320-60-3)
• EPA Substance Registry System: IMidazo[1,2-b]pyridazine, 3-[2-(triMethylsilyl)ethynyl]-(943320-60-3)

Safety Data

• Hazardous Substances Data: 943320-60-3(Hazardous Substances Data)

Usage

Description

Imidazo[1,2-b]pyridazine, 3-[2-(trimethylsilyl)ethynyl]is a chemical compound with the molecular formula C13H14N2Si. It is a derivative of imidazopyridazine, a heterocyclic compound containing both imidazole and pyridazine rings in its structure. Imidazo[1,2-b]pyridazine, 3-[2-(trimethylsilyl)ethynyl]3-[2-(trimethylsilyl)ethynyl]is a functional group attached to the imidazopyridazine core, consisting of a trimethylsilyl group and an ethynyl moiety. Imidazo[1,2-b]pyridazine, 3-[2-(trimethylsilyl)ethynyl]has potential applications in organic synthesis, medicinal chemistry, and material science due to its unique chemical structure and reactivity.

Uses

Used in Organic Synthesis:
Imidazo[1,2-b]pyridazine, 3-[2-(trimethylsilyl)ethynyl]is used as a building block for the synthesis of various organic compounds. Its unique chemical structure and reactivity make it a valuable intermediate in the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry:
Imidazo[1,2-b]pyridazine, 3-[2-(trimethylsilyl)ethynyl]is used as a potential lead compound in the development of new drugs. Its heterocyclic structure and functional group can be further modified to explore its biological activity and optimize its pharmacological properties.
Used in Material Science:
Imidazo[1,2-b]pyridazine, 3-[2-(trimethylsilyl)ethynyl]is used as a component in the development of new materials with specific properties. Its unique structure and reactivity can contribute to the design and synthesis of advanced materials for various applications, such as sensors, catalysts, and functional coatings.

Upstream product

• 18087-73-5 3-bromo-imidazo[1,2-b]pyridazine 
• 1066-54-2 trimethylsilylacetylene 
• 766-55-2 imidazo[1.2-b]pyridazine 
• 7486-35-3 tri-n-butyl(vinyl)tin 

Downstream Products

• 943320-61-4 3-ethynyl-imidazo[1,2-b]pyridazine 
• 1407999-83-0 C₂₉H₂₈F₃N₉O 
• 1428445-65-1 C₂₆H₂₆F₃N₉O 

Relevant articles and documents

N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES

The N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative exhibits excellent inhibitory activity against at least one kinase selected from the group consisting of ABL1, ABL2, AURKB, BRK, CDK11

COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS

The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables, RA, RB, RC, RD, L0, L1, L2

Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease

Parkinson's disease (PD) is a debilitating and common neurodegenerative disease. New insights implicating c-Abl activation as a driving force in PD have opened a new drug development avenue for PD treatment beyond the symptomatic relief by L-DOPA. BCR-Abl inhibitors, which include nilotinib and ponatinib, have been found to inhibit this process, and nilotinib has shown improvement in outcomes in a 12-patient, nonrandomized trial. However, nilotinib is a potent inhibitor of hERG, a cardiac K+ channel whose inhibition increases risk of sudden death. We used our machine learning approach to predict novel molecules that would inhibit c-Abl while also having minimal liability against hERG. Of our six novel compounds tested, we identified two that had c-Abl potencies comparable to nilotinib, but with significantly improved profiles regarding the hERG channel. Our best compound exhibited a hERG IC50 of 12.1 μM (compared to nilotinib with an IC50 of 0.45 μM and ponatinib with IC50 of 0.767 μM). This work is a step forward for a machine learning enabled, multiparameter optimization of a chemical space and represents a significant advance in the development of novel Parkinson's therapies.